Inventor · disambiguated record
Daniel Lundell
Also filed as: LUNDELL DANIEL
8 granted patents·3 pending applications·124 citations·filing 1995–2011
88Inventor score
Top patents by PatentIndex Score
11 records- 0194US7132445B23,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligandsPHARMACOPEIA DRUG DISCOVERY·Filed 2003·Granted Nov 7, 2006·58 cites·82 claims
- 0279US7960433B2Treatment of chemokine mediated diseasesSCHERING CORP·Filed 2007·Granted Jun 14, 2011·4 cites·11 claims
- 0376US7135555B2Mammalian TNF-α convertasesSCHERING CORP·Filed 2002·Granted Nov 14, 2006·3 cites·10 claims
- 0473US6531290B2Mammalian TNF- α convertaseSCHERING CORP·Filed 2001·Granted Mar 11, 2003·8 cites·3 claims
- 0572US5853977AMammalian TNF-α convertasesSCHERING CORP·Filed 1997·Granted Dec 29, 1998·27 cites·9 claims
- 0663US5744340AExpression of human inducible nitric oxide synthaseSCHERING CORP·Filed 1995·Granted Apr 28, 1998·17 cites·13 claims
- 0756US7358352B2Nucleic acids encoding human TNF-α convertaseSCHERING CORP·Filed 2006·Granted Apr 15, 2008·0 cites·6 claims
- 0853US6319681B1Mammalian TNF-α convertasesSCHERING CORP·Filed 1998·Granted Nov 20, 2001·7 cites·6 claims
- 0953US2007248594A1Cxcr1 and cxcr2 chemokine antagonistsSCHERING CORP·Filed 2007·Application pending·0 cites
- 1053US2011213029A13,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor LigandsSCHERING CORP·Filed 2011·Application pending·0 cites
- 1147US2004053953A1Treatment of chemokine mediated diseasesSCHERING CORP·Filed 2003·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →